Trial to gather data in support of an application for US pre-market approval (PMA)
Dublin - Ireland, 14 September 2016 - Mainstay Medical International plc ("Mainstay" or the "Company", Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain ("CLBP"), announces the enrolment of the first subject in the ReActiv8-B Clinical Trial ("the Clinical Trial"), which is intended to gather data in support of an application for pre-market approval (PMA) from the US Food and Drug Administration (FDA), a key step towards commercialization of ReActiv8 in the US.
The first subject was enrolled at the Genesis Research Services center in Newcastle, NSW, Australia by Dr. Marc Russo, and if all eligibility criteria are met, will be implanted with ReActiv8 within a few weeks. As more investigational sites are activated, the information at https://clinicaltrials.gov/show/NCT02577354 will be updated.
ReActiv8 is designed to electrically stimulate the nerves responsible for contracting muscles which stabilize the lumbar spine. Activation of these muscles to restore functional stability has been shown to facilitate recovery from CLBP. Mainstay received CE Marking for ReActiv8 in May 2016 based on positive results from the ReActiv8-A clinical trial which demonstrated a clinically important, statistically significant and lasting improvement in pain, disability and quality of life in people with disabling Chronic Low Back Pain and few other options.
Dr Chris Gilligan, Chief of the Division of Pain Medicine and Co-Director of the Spine Center at Beth Israel Deaconess Medical Center in Boston, MA, and Principal Investigator for the ReActiv8-B Clinical Trial said: "Chronic Low Back Pain is a major global challenge and many patients have been suffering from the condition for many years and are left with few treatment options. ReActiv8 offers a unique new approach which addresses cause and not simply symptoms. We look forward to gathering the clinical evidence required for Mainstay to make an application for PMA approval which would make ReActiv8 also commercially available to patients in the US."
Peter Crosby, CEO of Mainstay, commented: "The enrolment of the first subject in the ReActiv8-B Clinical Trial is yet another significant step for Mainstay this year following the CE Marking for ReActiv8 in May, triggering the start of commercialization activities in our first European market, Germany, and the raising of €30m new capital in June."
ReActiv8-B Clinical Trial
The ReActiv8-B Clinical Trial is an international, multi-center, prospective randomized sham controlled blinded trial with one-way crossover, conducted under an Investigational Device Exemption (IDE). The statistical design of the Clinical Trial requires data from the pivotal cohort of 128 randomized subjects at the 120-day primary outcome assessment visit.
The primary efficacy endpoint of the ReActiv8-B Clinical Trial is a comparison of responder rates between the treatment and control arms. The Clinical Trial will be considered a success if there is a statistically significant difference in responder rates between the treatment and control arms. The Clinical Trial, if successful, will provide what is referred to as Level 1 Evidence of safety and efficacy of ReActiv8, which may be used to support applications for favourable reimbursement in the USA. Evidence from the ReActiv8-B Trial will also be used to support market development activities worldwide.
Based on experience with enrolment in the ReActiv8-A Clinical Trial, it is estimated that full enrolment of the pivotal cohort in the ReActiv8-B Clinical Trial will take 12 to 18 months, with results anticipated to be available approximately six months following full enrolment.
Further details can be found at https://clinicaltrials.gov/show/NCT02577354.
CAUTION - in the United States, ReActiv8 is limited by federal law to investigational use only.
About Mainstay
Mainstay is a medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia and Germany, and its ordinary shares are admitted to trading on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).
About the ReActiv8-B Clinical Trial
The ReActiv8-B Clinical Trial is an international, multi-center, prospective randomized sham controlled blinded trial with one-way crossover conducted under an Investigational Device Exemption (IDE). The ReActiv8-B Clinical Trial is designed to generate data to form part of the Pre-Market Approval Application (PMAA) of ReActiv8 to the FDA. Further details can be found at https://clinicaltrials.gov/show/NCT02577354
About Chronic Low Back Pain
One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.
People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on individuals, families, communities, industry and governments.
Further information can be found at www.mainstay medical.com